



Premature circuit clotting during blood purification therapy with oXiris membrane: an observational multicenter study.

Gianluca Villa^{1,2}, Antonio Fioccola¹, Gaia Mari¹, Diego Pomarè Montin¹, Caterina Scirè- Calabrisotto¹, Silvia De Rosa³, Zaccaria Ricci^{1,4}, Claudio Ronco⁵, Stefano Romagnoli^{1,2}, for the oXirisNET registry working group.

¹ Department of Health Sciences, Section of Anesthesiology and Intensive Care, University of Florence, Florence, Italy

² Department of Anesthesia and Intensive Care, AOU Careggi, Florence, Italy
³ Department of Anaesthesia and Intensive Care, San Bortolo Hospital, Vicenza, Italy
⁴ Department of Anesthesia and Intensive Care, AOU Meyer, Florence, Italy
⁵ Department of Medicine, University of Padova, Padova, Italy; International Renal Research Institute of Vicenza, Vicenza, Italy; Department of Nephrology, San Bortolo Hospital, Vicenza, Italy.

Objective: To identify clinical features associated with premature circuit clotting during acute renal replacement therapies performed with an Oxiris hemodiafilter





Methods: Prospective, multicenter, observational study performed on data recorded into the oXirisNet Registry (www-arrt.eu).



PaO2/FiO2 ratio Serum Procalcitonine Haematocrit

<u>Results</u>: Patient's prescribed anticoagulation, paO2/FiO2 ratio, serum procalcitonin, and haematocrit were demonstrated to be independent predictors for circuit clotting.

Conclusion: The incidence of premature clotting among critically ill patients treated with heparin-coated hemodiafilters is 18.6%. Higher patients' haematocrit and no-anticoagulation strategies were associated with this phenomenon. Those patients who experienced premature filter clotting were characterized by a less important decline in SOFA score and less important organ function recovery.

